Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.44 |
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | HTR2C | P28335 | 4/20 | 0.44 |
| ▸ | HTR2B | P41595 | 4/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 2/20 | 0.36 |
| ▸ | ULK1 | O75385 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4899807 | 0.83 | ULK1 (0.43) | HTR1AHTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL4902716 | 0.80 | CDK1 (0.36) | HTR1AHTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL6518630 | 0.79 | HTR6 (0.50) | HTR6KIF11NPC1POLBRAB9A | |
| SCHEMBL4898904 | 0.77 | CYP1A2 (0.37) | HTR1AHTR6DHFRGAA | |
| SCHEMBL2134591 | 0.74 | FLT3 (0.58) | DRD2KIF11GLAGAAFLT3 | |
| SCHEMBL4891836 | 0.73 | ULK1 (0.42) | HTR1AHTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL915460 | 0.71 | HRH4 (0.55) | KIF11RAB9AGLAGAAFLT3 | |
| SCHEMBL30310659 | 0.71 | HRH4 (0.55) | KIF11RAB9AGLAGAAFLT3 | |
| SCHEMBL27558235 | 0.71 | DHFR (0.39) | HTR1ADRD2HTR6DHFR | |
| SCHEMBL2205092 | 0.70 | HRH4 (0.56) | KIF11GLAGAAFLT3ULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130331395-A1 | BRIDGED ARYL PIPERAZINES DERIVATIVES USEFUL FOR THE TREATMENT OF CNS, GI-URINARY AND REPRODUCTIVE DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-12 | — | — | US | disclosed |
| US-8530475-B2 | Serotonin reuptake inhibitors and antagonists of the serotonin 1A receptor; compounds are based on 7,9-diazabicyclo(4.2.2)dec-3-ene ring | JANSSEN PHARMACEUTICA NV | 2013-09-10 | — | — | US | disclosed |
| US-20080070919-A1 | BRIDGED ARYL PIPERAZINES DERIVATIVES USEFUL FOR THE TREATMENT OF CNS, GI-URINARY AND REPRODUCTIVE DISORDERS | CREIGHTON CHRISTOPHER J | 2008-03-20 | — | — | US | disclosed |
| WO-2007137168-A2 | BRIDGED ARYL PIPERAZINES DERIVATIVES USEFUL FOR THE TREATMENT OF CNS, GI-URINARY AND REPRODUCTIVE DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070919-A1 | BRIDGED ARYL PIPERAZINES DERIVATIVES USEFUL FOR THE TREATMENT OF CNS, GI-URINARY AND REPRODUCTIVE DISORDERS | HTR1A, HTR5A, TPH1 | HTR1A 1/4885HTR2A 7/4885HTR2C 9/4885 |
| US-20130331395-A1 | BRIDGED ARYL PIPERAZINES DERIVATIVES USEFUL FOR THE TREATMENT OF CNS, GI-URINARY AND REPRODUCTIVE DISORDERS | HTR1A, HTR5A, TPH1 | HTR1A 1/4885HTR2A 7/4885HTR2C 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.